Sirnaomics to Present at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery

Tuesday, March 12, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

GAITHERSBURG, Md., March 11, 2019 /PRNewswire/ -- Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and

development of RNAi therapeutics against cancer and fibrotic diseases, today announced that the Company's management will present its platform technology and discuss the potential utility of RNAi therapeutics at the 4th Annual Oligonucleotide
& Precision Therapeutics: Discovery, Development and Delivery conference on March 25-28, 2019 in Cambridge, Massachusetts.

Patrick Lu, PhD, President and Chief Executive Officer, will share an overview of Sirnaomics' differentiated RNAi technology platform, which leverages a proprietary polypeptide nanoparticle (PNP) drug delivery system, and the Company's pipeline of RNAi therapeutics spanning oncology and anti-fibrosis indications at the following presentations.

  • Presentation: Chairperson's RemarksDate & Time: March 26, 10:45 am ET
  • Presentation Title: Novel siRNA Therapeutics for Immune Oncology TherapeuticsPresentation Track: Oligonucleotide Discovery and DeliveryDate & Time: March 26, 2 pm ET
  • Presentation Title: Can We Push for siRNA Cancer Therapeutics Similar to Experiences with mAbs?Date & Time: March 27, 8 am ET

Also, Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics, will chair a short course, "Examining The Safety and Toxicity of Nucleic Acid Therapeutics", on Monday, March 25 starting at 6:50 pm ET. He will also participate in a panel discussion, "Bridging the Gap between Discovery, Development and Compliance", on Tuesday, March 26 at 9:15 am ET.

About Sirnaomics, Inc.

Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company's mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors, corporate partnerships and government grants. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.

CONTACT:

Sirnaomics, Inc. Michael Molyneaux MD MBA Chief Medical Officermichaelmolyneaux@sirnaomics.com

ICR Healthcare Investors:Stephanie CarringtonTel: +1 646 277 1282 Email: Stephanie.Carrington@icrinc.com 

Media: James Heins Tel: +1 203 682 8251Email: James.Heins@icrinc.com

Cision View original content:http://www.prnewswire.com/news-releases/sirnaomics-to-present-at-the-4th-annual-oligonucleotide--precision-therapeutics-discovery-development-and-delivery-300810415.html

SOURCE Sirnaomics, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store